CD5.CAR/28 T Cells, Cyclophosphamide, and Fludarabine in Treating Participants with Recurrent T-Cell Malignancies Expressing the CD5 Antigen

Inclusion Criteria

• INCLUSION - PROCUREMENT: Referred patients will initially be consented for procurement of blood for generation of the transduced ATL; eligibility criteria at this stage include: * Diagnosis of recurrent T-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including angioimmunoblastic T-cell lymphoma [AITL], enteropathy-associated T-cell lymphoma [EATL], monomorphic epitheliotropic intestinal T-cell lymphoma [MEITL], peripheral T-cell lymphoma [PTCL] not otherwise specified [NOS], anaplastic large cell lymphoma [ALCL] adult T-cell leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, extranodal natural killer [NK]/T cell lymphoma, mycosis fungoides/ Sezary syndrome stage IIb or higher) AND GROUP A: Suitable for allogeneic HSCT with confirmation of an identified eligible allogeneic (allo)-HSCT donor by a Foundation for the Accreditation of Cellular Therapy (FACT) accredited transplant center GROUP B: Relapsed post-allogeneic HSCT with previous HSCT donor from whom allogeneic MAGENTA CAR T cells can be manufactured AND * with confirmation that the center plans to proceed with transplant if CD5.CAR treatment induces a complete remission ** For T-NHL subjects, eligibility will be confined to disease stages where allogeneic HSCT is indicated
• INCLUSION - PROCUREMENT: CD5-positive tumor (result can be pending at this time); > 50% CD5 + blasts by flow cytometry or immunohistochemistry (tissue) assessed by a Clinical Laboratory Improvement Amendments (CLIA) certified flow cytometry/pathology laboratory
• INCLUSION - PROCUREMENT: Age ≤ 75 years old. The first six (6) patients treated on the study should be adults (≥ 18 years [yrs] of age)
• INCLUSION - PROCUREMENT: Hemoglobin (Hgb) > 7.0 (can be transfused)
• INCLUSION - PROCUREMENT: Life expectancy greater than 12 weeks
• INCLUSION - PROCUREMENT: If pheresis required to collect blood: * Creatinine <1.5 × upper limit normal
• INCLUSION - PROCUREMENT: If pheresis required to collect blood: * Aspartate aminotransferase (AST) < 1.5 × upper limit normal
• INCLUSION - PROCUREMENT: If pheresis required to collect blood * Prothrombin time (PT) and activated partial thromboplastin time (APTT) <1.5 × upper limit normal
• INCLUSION - PROCUREMENT: Informed consent explained to, understood by and signed by patient/guardian; patient/guardian given copy of informed consent
• INCLUSION - TREATMENT: Diagnosis of recurrent T-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including angioimmunoblastic T-cell lymphoma [AITL], enteropathy-associated T-cell lymphoma [EATL], monomorphic epitheliotropic intestinal T-cell lymphoma [MEITL], peripheral T-cell lymphoma [PTCL] NOS, anaplastic large cell lymphoma [ALCL], adult T-cell leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, extranodal NK/T cell lymphoma, mycosis fungoides/ Sezary syndrome stage IIB or higher) AND GROUP A: Suitable for allogeneic hematopoietic stem cell transplant (HSCT) with confirmation of an identified eligible allo-HSCT donor by FACT accredited institution GROUP B: Relapsed post-allogeneic HSCT with previous HSCT donor from whom allogeneic MAGENTA CAR T cells can be manufactured AND * with confirmation of an identified eligible allo-HSCT donor by a FACT accredited transplant center AND * with confirmation that the center plans to proceed with transplant if CD5.CAR treatment induces a complete remission ** For T-NHL subjects, eligibility will be confined to disease stages where allogeneic HSCT is indicated
• INCLUSION - TREATMENT: Age ≤ 75 years old. NOTE: The first six (6) patients treated on the study should be adults (≥ 18 yrs of age)
• INCLUSION - TREATMENT: Bilirubin less than 3 times the upper limit of normal
• INCLUSION - TREATMENT: AST less than 5 times the upper limit of normal
• INCLUSION - TREATMENT: Estimated glomerular filtration rate (GFR) > 60 mL/min
• INCLUSION - TREATMENT: Pulse oximetry of > 90% on room air
• INCLUSION - TREATMENT: Karnofsky or Lansky score of >= 60%
• INCLUSION - TREATMENT: Recovered from acute toxic effects of prior chemotherapy at least one week before entering this study
• INCLUSION - TREATMENT: ≥ 60 days post-allogeneic HSCT at time of treatment
• INCLUSION - TREATMENT: Life expectancy of greater than 12 weeks
• INCLUSION - TREATMENT: Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condom
• INCLUSION - TREATMENT: Informed consent explained to, understood by, and signed by patient/guardian; patient/guardian given copy of informed consent

Exclusion Criteria

• EXCLUSION - PROCUREMENT: Active infection requiring antibiotics
• EXCLUSION - PROCUREMENT: Active infection with human immunodeficiency virus (HIV) or human T-lymphotropic virus (HTLV)
• EXCLUSION - PROCUREMENT: Clinically significant viral infection or uncontrolled viral reactivation of Epstein Barr virus (EBV), cytomegalovirus (CMV), adenovirus (Adv), BK-virus, or human herpesvirus 6 (HHV-6)
• EXCLUSION - PROCUREMENT: History of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least 2 years before trial entry
• EXCLUSION - TREATMENT: Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks
• EXCLUSION - TREATMENT: History of hypersensitivity reactions to murine protein-containing products
• EXCLUSION - TREATMENT: Pregnant or lactating
• EXCLUSION - TREATMENT: Tumor in a location where enlargement could cause airway obstruction
• EXCLUSION - TREATMENT: Active infection with HIV
• EXCLUSION - TREATMENT: Clinically significant viral infection or uncontrolled viral reactivation of EBV, CMV, Adv, BK-virus, or HHV-6
• EXCLUSION - TREATMENT: Evidence of acute GVHD > Grade II or active chronic GVHD > mild global severity score
• EXCLUSION - TREATMENT: Currently taking corticosteroids for therapy of GVHD at a dose of > 0.5mg/kg prednisone equivalent
• EXCLUSION - TREATMENT: Patients who have received Immunosuppressive Treatment (IST) for GVHD within 28 days of infusion
• EXCLUSION - TREATMENT: Patients who have received donor lymphocyte infusion (DLI) within 28 days of infusion
• EXCLUSION - TREATMENT: Any of the following cardiac criteria: atrial fibrillation/flutter; myocardial infarction within the last 12 months; prolonged QT syndrome or secondary prolonged QT, per investigator discretion. Cardiac echocardiography with LVSF =< 30% or LVEF =< 50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA III or IV (Confirmation of absence of these conditions within 12 months of treatment)
• EXCLUSION - TREATMENT: Central nervous system (CNS) abnormalities: presence of CNS-3 disease defined as detectable cerebrospinal blast cells in a sample of cerebrospinal fluid (CSF) with ≥ 5 white blood cells (WBCs) per mm^3; history or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement